Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: Implications for cancer therapy

EMBO Journal

Volumn 21, Issue 10, 2002, Pages 2407-2417

  Citri, Ami ^a   Alroy, Iris ^a   Lavi, Sara ^a   Rubin, Chanan ^b   Xu, Wanping ^c   Grammatikakis, Nicolas ^d   Patterson, Cam ^e   Neckers, Len ^e   Fry, David W ^f   Yarden, Yosef ^f  

^a DIVISION OF REPRODUCTIVE BIOLOGY   (United States)

^b UNIVERSITY OF LONDON   (United Kingdom)

^c RESEARCH AND DEVELOPMENT   (Australia)

^d College of Chemistry and Molecular Engineering ^*  (China)

^e UNIVERSITY OF SHEFFIELD   (United Kingdom)

^f WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Geldanamycin; Growth factor; Protein kinase inhibitors; Stress response; Ubiquitin

Indexed keywords

4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; 6,7 DIMETHOXY 2 PHENYLQUINOXALINE; CANERTINIB; CHAPERONE; CYSTEINE; ERBB RECEPTOR TYROSINE KINASE; GELDANAMYCIN; GENISTEIN; HEAT SHOCK PROTEIN 90; LACTACYSTIN; ONCOPROTEIN; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; TRASTUZUMAB; UBIQUITIN; UNCLASSIFIED DRUG;

ALKYLATION; ARTICLE; BINDING SITE; CANCER THERAPY; CONTROLLED STUDY; ENDOCYTOSIS; ENZYME DEGRADATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; ONCOGENE NEU; PRIORITY JOURNAL; PROTEIN TARGETING; TUMOR GROWTH;

ANTINEOPLASTIC AGENTS; BENZOQUINONES; CELL DIVISION; CELL LINE; ENDOCYTOSIS; ENZYME INHIBITORS; HUMANS; LACTAMS, MACROCYCLIC; MORPHOLINES; NEOPLASMS; PROTEIN-TYROSINE KINASES; QUINONES; RECEPTOR, ERBB-2; RECOMBINANT PROTEINS; TRANSFECTION; UBIQUITIN;

EID: 18444404925     PISSN: 02614189     EISSN: None     Source Type: Journal    
DOI: 10.1093/emboj/21.10.2407     Document Type: Article

References (32)

1. The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome
2. Intracellular expression of single chain antibodies reverts ErbB-2 transformation
3. Hsp90 & Co. - A holding for folding
4. p185erbB2 binds to GRP94 in vivo. Dissociation of the p185erbB2/GRP94 heterocomplex by benzoquinone ansamycins precedes depletion of p185erbB2
5. Site-directed irreversible inhibitors of the erbB family of receptor tyrosine kinases as novel chemotherapeutic agents for cancer
6. Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor
7. Tyrphostins IV - Highly potent inhibitors of EGF receptor kinase. Structure-activity relationship study of 4-anilidoquinazolines
8. Therapy of an animal model of human gastric cancer using a combination of anti-ErbB-2 monoclonal antibodies
9. A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors
10. Tumorinhibitory antibodies to HER-2/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2
11. Protein tyrosine kinase inhibitors as novel therapeutic agents
12. Ubiquitin ligase activity and tyrosine phosphorylation underlie suppression of growth factor signaling by c-Cbl/Sli-l
13. c-Cbl is a suppressor of the neu oncogene
14. Differential heat stress stability of epidermal growth factor receptor and ErbB-2 receptor tyrosine kinase activities
15. Polyubiquitination and proteasomal degradation of the p185c-ErbB-2 receptor proteintyrosine kinase induced by geldanamycin
16. Accelerated degradation of 160 kDa epidermal growth factor (EGF) receptor precursor by the tyrosine kinase inhibitor herbimycin A in the endoplasmic reticulum of A431 human epidermoid carcinoma cells
17. Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy
18. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers
19. Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene
20. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions
21. Disruption of the Raf-1-Hsp90 molecular complex results in destabilization of Raf-1 and loss of Raf-1-Ras association
22. Herbimycin A induces the 20 S proteasome- and ubiquitin-dependent degradation of receptor tyrosine kinases
23. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
24. Tyrosine kinase inhibitors. 18. 6-substituted 4-anilinoquinazolines and 4-anilinopyrido[3, 4-d] pyrimidines as soluble, irreversible inhibitors of the epidermal growth factor receptor
25. Recognition of the polyubiquitin proteolytic signal
26. Geldanamycin induces ErbB-2 degradation by proteolytic fragmentation
27. Anticancer efficacy of the irreversible EGFr tyrosine kinase inhibitor PD 0169414 against against human tumor xenografts
28. Sensitivity of mature ErbB2 to geldanamycin is conferred by its kinase domain and is mediated by chaperone protein Hsp90
29. Hsp90, not Grp94, regulates the intracellular trafficking and stabilty of nascent ErbB2
30. Untangling the ErbB signalling network
31. Identification of a geldanamycin dimer that induces the selective degradation of HER-family tyrosine kinases